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“Parkinson’s Disease (PD) is a progressive neurodegenerative disease characterized by the loss of dopaminergic (DA) neurons in the 
substantia nigra,” negatively affecting motor control and causing symptoms such as dyskinesia, or uncontrollable, involuntary muscle 
movement1. The purpose of this study was to explore a safe, affordable, and accessible method of treatment for such symptoms. It was 
hypothesized that when  Mucuna  pruriens (Mpe) and Brassica oleracea (B. oleracea) extracts are administered to PINK1 Drosophila , 
Brassica oleracea would delay the loss of motor ability in the PINK1 flies the longest because it contains sulforaphane which activates 
the Nrf2 pathway, promoting antioxidant activity and countering oxidative stress. To quantify the climbing ability of the PINK1 
Drosophila, which display PD-like symptoms, a climbing assay was conducted on the treatment groups, where the flies were 
administered either 32mg/100g Mpe or B. oleracea, and the control group, which was administered nothing. After running an ANOVA 
and t-test on the results of this experiment, it was determined that only Mpe had a significant effect on the climbing ability of PINK1 
Drosophila. The t-test displayed that the difference between the Mpe treatment group and the control group was significant, but the 
difference between the B. oleracea treatment group and the control was not statistically significant. Therefore, only Mpe effectively 





“Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease in the world”1. Seven to ten million people suffer from this 
disease everyday2. PD is a “characterized by the selective loss of dopaminergic (DA) neurons in the substantia nigra,” a basal ganglia structure of 
the midbrain that is responsible for the regulation of movement and reward1. With both motor and non-motor symptoms, PD is a chronic 
progressive disease that impairs quality of life, health, and movement. Motor symptoms discussed in this paper include tremor, bradykinesia, and 
rigidity, which are characterized by the loss of controllable movement. Because there is no known cure for PD, most therapeutic treatments are 
aimed at alleviating symptoms. However, there is a lack of treatments that aim towards the reversal or regression of the disease3. Therefore, there is 
concern regarding the availability and effectiveness of the common symptomatic treatments for Parkinson's disease. Although clinical studies have 
been performed to explore a cure, many developing countries would still not be able to access it. According to scholars in the Department of 
Elderly Medicine at North Tyneside General Hospital, “the majority of people with PD in sub-Saharan Africa are undiagnosed and untreated, 
resulting in impaired quality of life and increased mortality rates”4. Therefore, finding a safe, affordable, and effective method of treatment using 
Ayurvedic extracts is the aim of this comparative study. 
The conducted study targets various properties possessed by Aryuvedic extracts and their preventative abilities. Traditional Ayurvedic 
medicine, commonly practiced in Asian countries, exercises the use of herbal treatments to treat many ailments, such as wound healing and even 
liver disorders5. Because of the availability of these natural therapeutic agents, they are a favorable alternative to those who can not afford 
sustainable healthcare. Clinical studies have been conducted on various Ayurvedic agents with healing properties, but because Brassica oleracea 
and Mucuna Pruriens have so rarely been studied on PINK1 drosophila, and seldom compared, this study fills that gap by exploring the differences 
in their properties that would lead to their success or failure in trying to slow the regression of the flies’ impaired climbing ability. This study 
compares various properties of each plant extract in order to determine the factors that most contribute to the prolonging of loss of motor 




Disadvantages of Current Treatments for Parkinson’s Disease 
 
Although PD is mainly caused by genetic factors, mitochondrial dysfunction, and inflammation are main causes of the strenuous motor 
symptoms3. Apoptosis (selective cell death) and oxidative stress, or the imbalance between antioxidants and free radicals in one’s body also play a 
role. Many researchers have been working to find treatments throughout the years, but with these causes, disorders such as bradykinesia, rigidity, 
tremor-at-rest, flexed posture arise, and loss of postural reflexes continually cause uncontrollable movement of the body6.  
As of now, the “golden standard” medication for PD is L-DOPA, which can cross the protective blood-brain barrier where the central nervous 
system converts it into dopamine, increasing its concentrations in the brain7. However, long term use of L-DOPA can even induce dyskinesia, or the 
impairment of voluntary movement. This problem has been mitigated by using dopamine agonists to lessen the use of L-DOPA, but his could cause 
a greater risk of drug reaction and has been known to cause side effects, such as ankle and leg oedema, impulse control disorders, hallucinations, 
confusion and psychosis. Similarly, Amantadine, another dopamine agonist, has been used as an antidyskinetic agent to reduce the L-DOPA 
induced dyskinesia, but the effects of this also lessen over time6. However, current treatments are not easily accessible, nor are they affordable for 
those who lack resources. There is currently a lack of universal L-DOPA availability, which can be presently seen in various countries8. Therefore, 
this study will compare a more natural remedy (Brassica oleracea) with a potential L-DOPA replacement (Mucuna pruriens), in order to further 
explore safer, long-term treatment options for the motor symptoms of PD.  
Antioxidant and Protective Properties of Brassica oleracea  
Oxidative stress, a major cause of PD, is expressed as a factor that “leads to a decrease in antioxidant pathways, resulting in altered oxygen 
consumption and interrupted redox homeostasis” 9. It is characterized by an imbalance of the free radicals and the body’s ability to detoxify and 
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repair the damage caused by the unstable atoms. There is evidence suggesting that increased damage to lipids, proteins, and DNA is caused by 
oxidative stress10. However, sulforaphane is a phytochemical found in Brassica oleracea (B. oleracea) that is said to prevent oxidative stress-
induced cytotoxicity through the activation of the Nrf2-antioxidant responsive pathway, which can protect the body against free radicals11. A study 
completed in 2010, by professors at the University of Ulsan College of Medicine, in the Department of Biochemistry and Molecular Biology, 
suggests that Sulforaphane can also benefit the alleviation of symptoms by protecting dopaminergic cells from cytotoxicity through the removal of 
intracellular Dopamine quinones and degrading misfolded proteins12. Similarly, as demonstrated by previous researchers in a study that used 
Rotenone to induce neurodegeneration, Sulforaphane inhibited apoptosis of neurons through the restoration of the mTOR pathway. Furthermore, it 
reduced dopaminergic neurodegeneration and corrected oxidative damage by activating the Nrf2 pathway13. By regulating the cells and allowing 
for antioxidant activity, B. oleracea presents as a promising future treatment for PD. 
L-DOPA Containing Herbal Remedy: Mucuna pruriens 
Unlike the previously mentioned agent, Mucuna pruriens (Mpe) can be used to combat PD because they contain L-DOPA, which increases 
dopamine concentration, making it one of the most effective extracts for alleviating PD symptoms7.In a study done by professors of biotechnology, 
health sciences, and neuroscience, using Drosophila and Caenorhabditis elegans, Mpe was shown to have reduced hydrogen peroxide-induced 
cytotoxicity and ameliorated dopaminergic concentration, due to its L-DOPA content14. However, in a 2014 study done by Poddighe et al., from the 
department of Biomedical Sciences at the University of Cagliari, Mpe was found to have increased the tyrosine hydroxylase levels and restored 
damaged mitochondria, independently of L-DOPA. They also discovered that the administration of 0.1% Mpe greatly reduced PINK1 mutants’ 
motor impairment7. Mpe has a reduced level of L-DOPA than the “golden standard” L-DOPA, but redeems its worth through the other biological 
agents that improve the motor symptoms of PD. In another 2014 study by Jansen et al., “L-DOPE treated flies had a significantly decreased 
climbing ability compared with Zandopa,” which contains Mpe6. This further induces the notion that Mpe has intrinsic properties that act to delay 
loss of motor ability. However, according to a 2015 article, long term consumption of Mucuna pruriens has also been linked to vomiting, nausea, 
abdominal distention, spermatogenic loss, etc.15. In this study, it will be determined if Mpe can act as an alternative for direct administration of L-
DOPA, since it is associated with less serious long term side effects and can potentially mitigate the issue of the L-DOPA unavailability.  
PINK1 Drosophila melanogaster as a Model Organism for PD 
D. melanogaster PINK1 mutants display several phenotypic characteristics of PD, including dopaminergic neurodegeneration, mitochondrial 
dysfunction, and locomotor defects16. The PINK1 gene, which is responsible for encoding mitochondrially targeted protein kinase, plays a key role 
in mitochondrial quality control through phosphorylation of chaperones (assistants of conformational folding or unfolding), and regulation of 
mitophagy, or the elimination of dysfunctional mitochondria to protect cells from damage. Once PINK1 gathers on the outer membrane of a 
damaged mitochondria, Parkin (another gene) is activated, which triggers selective autophagy, where damaged cells are eliminated17. Consequently, 
mutations in the PINK1 gene can lead to an increase in damaged protein/mitochondria, which can further cause oxidative stress or death of healthy 
cells. PINK1 is commonly associated with PD because it displays these qualities. Therefore, this study utilized PINK1 mutant Drosophila as a 
model of Parkinson’s disease. It was hypothesized that when  Mucuna  pruriens (Mpe) and Brassica oleracea (B. oleracea) extracts are administered 
to PINK1 Drosophila , Brassica oleracea would delay the loss of motor ability in the PINK1 flies the longest because it contains sulforaphane 
which activates the Nrf2 pathway, promoting antioxidant activity and countering oxidative stress. A climbing assay was conducted to quantify the 




The PINK1 Drosophila from the Bloomington Stock center were transferred into a culture chamber upon arrival. PINK1 Drosophila were used 
because of their mutation that causes them to have Parkinson-like symptoms9. The following ratio of the Drosophila food/water/yeast was adapted 
from Carolina Biological’s instructions to account for the dosage that was later administered. 0.75 oz of Drosophila food medium and 0.75 oz of 
tap water were placed at the bottom of the culture chamber 6. 5-10 grains of Fleischmann's Active Dry Yeast were also placed on the medium18. 
Furthermore, netting was placed into the chamber. Two minutes after the medium settled, the container that the PINK1 Drosophila had initially 
come in was tapped against a surface to cause the flies to fall to the bottom of the container, thus preventing them from escaping. Then, the plug 
was removed, and the container was flipped and tapped to transfer the flies to a new container. Larvae were left in the container that they had 
arrived in for growth to adulthood. Once flies emerged, they were transferred to the new chamber as well. The culture chamber was left out of 
direct sunlight, in a shaded environment at 23 degrees Celsius19. 
After their period of growth, which lasted 12 days, the flies were anesthetized with FlyNap. Gloves and safety goggles were used during this 
process. The wand provided by Carolina Biological was dipped into the FlyNap solution once. The plug for a fly chamber was removed and the 
wand was left in the top corner of the chamber for 4 minutes. The wand and plug were removed. After being anesthetized, the flies were counted 
and equally distributed into three separate culture chambers with at least 20 flies in each container. The procedures for creating the initial culture 
chamber were used to set up the next three. In two separate chambers, 8 milligrams of Mucuna  pruriens and Brassica oleracea extract were mixed 
in with fly medium6. In a 2014 experiment done by Jansen et al., from the School of Agriculture, Food and Rural Development at Newcastle 
University, dosages that have been used in human trials were equated to the dosages used for the flies per 100g of medium. Since 12.3–31.8 mg of 
M. prurien extract were suggested for use on Drosophila, the ratio of 32mg/100g was used for the M. prurien extract. In a similar study,  Bellew-
Dunn administered B. oleracea extract at 1% w/w. However, because high doses of B. oleracea extract can be detrimental to Drosophila and 
32mg/100g is a ratio that is less than 1% w/w, the B. oleracea extract was administered at 32mg/100g to control the confounding variable of dosage 
difference20. The last chamber contained a standard fly medium.  
On the day of administration of the extracts, a negative geotaxis, or climbing assay was conducted. For this procedure, 20 flies from an 
experimental group were placed in a 20 cm × 2.5 cm glass graduated cylinder. They were tapped down in a vial before starting to climb21. The flies 
were allowed 10 seconds to acclimate per trial. The number of flies passing the 8 cm mark in this time was recorded for each trial22. These flies 
were labeled as “escaped” flies. In a study done by Rose et al., from the Department of Life and Environmental Sciences, at the University of 
Cagliari, the percentage of flies that crossed a certain mark in a vial was recorded for each trial22. A study done by Siddique et al. viewed the 
climbing ability of Drosophila over time, by doing similar trials every 3 days for 24 days5. The methods of these studies were adapted in the 
conducted study. Therefore, in the current study, there were 5 trials for each experimental group.  The mean percentage of flies that had passed the 
8cm mark in ten seconds was calculated.  Due to the limitation of time, this process was repeated every other day, for only 16 days, in order to 
determine the effectiveness of the extracts in delaying the loss of motor ability over time5. This methodology for experimentation allows for the 
deterioration or rescue of motor ability in Drosophila over time to be viewed. A two-way ANOVA and a post-hoc t-test were conducted using 
Excel to determine the significance of the results7. 
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Results  
 
To quantify the climbing ability of PINK1 Drosophila, A climbing assay was conducted using a 20 cm × 2.5 cm graduated cylinder. After data 
was collected, the results of the climbing assays of the controlled group were compared to those of the experimental groups. After 5 trials were 
conducted each day, using 20 flies in each trial, the average number of flies and the percentage of flies that “escaped” per trial was recorded in 
Tables 2 and 3. The data in these Tables were adapted from Appendix 1, which displays the raw data collection. In this study, the flies that had been 
administered with Mucuna  pruriens extract had displayed a greater average percentage of escaped flies over the course of the 16 day period. 
However, the flies that received the Brassica oleracea treatment, had shown results that were similar to the control group.  
The statistics summary, seen in Table 4, was calculated to observe differences in the sum and average amounts in the percentage of flies 
“escaped.”  The average percentage of escaped flies for the control group is 33.22, which is similar to that of the B. oleracea treatment group’s 
average of 36.55. However, the average percentage of flies that escaped in the Mpe treatment group was around 53.44, which is a higher average 
than those of the other two groups. Similarly, the sum of escaped flies for the control group is 299, which is similar to that of the B. oleracea 
treatment group’s sum of 329. Both of these values are lower than the sum of flies escaped after being treated with Mpe extract (481). The variance 
level for the Mpe treatment group is 65.03, which is much lower than that of the control group (328.69) and the B. oleracea treatment group 
(307.03). The climbing ability of the Mpe treatment group did not decrease as drastically as those of the flies in other groups. 
An ANOVA Two-Factor Without Replication was conducted to analyze the significance of this data. The ANOVA in Table 5 was conducted 
instead of the ANOVA Two-Factor with Replication because the conducted study compares multiple groups of individuals performing one task. 
There was substantial evidence to reject the null hypothesis that the ayurvedic extracts did not affect the climbing ability of PINK1 Drosophila 
melanogaster.  The F-value of 24.34 on the first row was greater than the critical value of 3.63, supporting that the treatment did have a significant 
effect on the flies’ climbing ability. With a p-value of 1.4E-05, which is <0.00001, and an alpha value of 0.05, it can be determined that there was a 
statistically significant difference between effects that the extracts had on the percentage of flies that “escaped.” Also, the F-value of 14.12 on the 
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second row was greater than the critical value of 2.59, supporting the notion that time had a significant effect on the flies’ (loss of) climbing ability. 
This can also be deducted from the p-value of 6.52E-06, which indicates statistical significance when compared to an alpha value of 0.05, since the 
p-value is less than the alpha value. Following the ANOVA, a post-hoc t-test was conducted.  
The t-test shown in Table 6 was conducted to determine if there was a significant difference between the climbing ability of the control group 
and the Mpe treatment group, the control group and the B. oleracea treatment group, and the Mpe treatment group fescue and B. oleracea treatment 
group. The resulting p-value when comparing the control group and the Mpe treatment group was 0.003761, which is less than the alpha value of 
0.5, meaning that the difference between these two conditions is significant. However, the resulting p-value when comparing the control group and 
the B. oleracea treatment group was 0.348447, which is larger than the alpha value of 0.5, meaning that the difference was not significant. Finally, 
when comparing the Mpe treatment group fescue and B. oleracea treatment group the resulting p-value was 0.009158, which is less than the alpha 
value of 0.5, meaning that the difference was significant. From this t-test, it can be observed that Mpe treatment had more of an impact on the 
climbing ability of PINK1 Drosophila than the Mpe treatment did, since it displayed the longest delay in loss of motor ability.  
As can be seen in Figure 2, the line graph, and in Table 3, the PINK1 flies that were administered Mpe extract displayed a significant delay in 
the loss of climbing ability, as compared to the control group. Conversely, the flies that were administered B. oleracea extract did not display a 
significant delay or acceleration of loss in climbing ability. Therefore, the B. oleracea extract did not have an effect on the flies. Furthermore, there 
was a significant difference between the experimental groups, signifying the difference in effect that Mpe had, in comparison to B. oleracea. Figure 
1 provides a visual representation of the delaying effect that Mpe had on the climbing ability of the PINK1 flies. 
Similarly, it can be seen in Figure 3 and Table 7 that on the last day of data collection, the climbing ability of the group that was administered 
Mpe was significantly affected, when compared to those of the B. oleracea treatment group and the control group. In the box plot, the X that 
displays the mean number of flies escaped is similar between the B. oleracea treatment group (3) and the control group (2.6). However, the value of 
the mean number of flies that escaped in the Mpe treatment group (8) was significantly higher. The box plot provides a visual representation of the 




This study was conducted to delay and alleviate the motor symptoms of Parkinson’s Disease (PD) in Drosophila melanogaster through the 
administration of ayurvedic extracts. By measuring the climbing ability of the flies, over the course of 16 days, and comparing those results, the 
effectiveness of Brassica oleracea and Mucuna  pruriens extracts was determined. As this model serves to represent PD in humans, it is 
acknowledged that it may be applicable to future trials on humans. As many developing countries do not have access to the advanced healthcare 
that is in the United States, the purpose of this experiment was to find a safe and affordable method of treatment for this disease.  
The hypothesis of the conducted study was that when  Mucuna  pruriens and Brassica oleracea extracts are administered to PINK1 Drosophila , 
Brassica oleracea would delay the loss of motor ability in the PINK1 flies the longest because it contains sulforaphane which activates the Nrf2 
pathway, promoting antioxidant activity and countering oxidative stress. However, the hypothesis was not supported. The t-test displayed that the 
B. oleracea treatment had no significant effect on the climbing ability of PINK1 Drosophila. On the other hand, the Mpe treatment did significantly 
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affect the climbing ability of PINK1 Drosophila, as it slowed the loss of motor ability. This finding can be applied to human clinical trials, where 
Mpe treatment could potentially be used to delay the loss of motor ability that is caused by PD. Since Mpe is more accessible to those in developing 
countries, those who cannot afford professional treatment could use this as an alternative aide. 
In a 2014 study conducted by professionals in the fields of nanochemistry, molecular science, neuroscience, pharmacology, etc, it was found 
that Mpe (0.1% L-DOPA) treatment significantly improved the climbing activity by 76% in PINK1B9 mutant flies by reducing the trend of 
worsening climbing rate7. However, in another 2014 study, done by scholars in the departments of Agriculture, Biology, and Biomedicine, “Mpe 
treatment did not result in a significant effect on climbing ability in the PINK1 flies,” only increasing the climbing ability by 31.7%6. The results of 
the conducted study displayed that Mpe did significantly delay the loss of climbing ability in PINK1 Drosophila, although it did not increase it. By 
the end of the 16 day period, the Mpe treatment group had 27% more escaped flies than the control group. These results of the conducted study can 
be justified by the properties of Mpe, which prevent hydrogen peroxide-induced cytotoxicity and regulate dopaminergic concentration through the 
chemical, L-DOPA14. As Mpe is a plentiful source of L-DOPA, it is known to be used to increase dopamine concentration in the brain, which PD 
depletes. Because Mpe helped replenish the dopaminergic concentration in the substantia nigra, it showed a steady delay of loss of climbing ability, 
in comparison to the control group of flies, which lost climbing ability much more rapidly. However, it is believed that Mpe contains healing 
properties that are unrelated to its L-DOPA content, which may have contributed to its success in delaying the motor symptoms of PD15. 
In a study conducted by a bachelor of science at Lancaster University, it was found that when flies were administered with B. oleracea, “there 
was no significant change in fly performance at any given time point, nor any change in performance decline over time” 20.The conducted 
experiment produced similar results, displaying an insignificant effect of B. oleracea on climbing ability. However, another study conducted by 
scholars in the department for life quality studies, claim that sulforaphane, which is plentiful in B. oleracea, is preventative against oxidative stress-
induced cytotoxicity through the activation of the Nrf2-antioxidant pathway and removal of intracellular DA quinone and degrading the misfolded 
protein11. It is believed that the B. oleracea treatment was unsuccessful in slowing the regression of climbing rate in Drosophila because the dosage 
level and administration were not sufficient. This study was unable to administer a dosage of B. oleracea that is proportionate to the ratio that 
would be used in humans, due to the lack of studies regarding its use on Drosophila. As a result, the same dosage used for Mpe was used for B. 
oleracea, in hopes of controlling the variable of unequal dosage. However, as a model of Parkinson’s disease, using the same concentration was not 
representative of the dosage that would likely have been used in human trials. This error can justify the lack of motor improvement that the flies 
administered with B. oleracea displayed. Similarly, it is believed that the chemical Sulphoraphone, when administered directly, could delay the 
symptoms of PD better than it’s oral administration through B. oleracea. It is also possible that the Nrf2-antioxidant pathway has no effect on the 
gene mutation.  
A source of uncertainty during the experiment was the age of flies. Because of the minimal number of flies that arrived upon order, time had to 
pass for the next generation of Drosophila to reach adulthood. Due to this factor, it was not guaranteed that all of the flies were the same age, 
although all of them were in the adult stage. It is possible that some flies from the previous generation survived long enough to endure the first trial 
of data collection. 
The conducted study could improve its procedure by using a B. oleracea extract dosage that is most proportionate to drug dosages that would 
be used in humans. In future experimentation, it would also be preferable to have a more plentiful number of flies, for a larger number of trials to 
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make the current experiment more accurate. Similarly, a positive and negative control for this experiment should have been implemented. Rather 
than just having untreated PINK1 flies, using Wild Type flies would allow for a model of normal fly behavior (without the gene mutation).  
In the future, having multiple tests, such as a crawling assay, survival rate, along with the climbing assay, would allow one to discover the 
effects of the extracts on multiple factors. Moreover, another potential study would be to be able to experiment with more extracts, specifically ones 
that target apoptosis and inflammation, rather than mitochondrial damage or oxidative stress (which were focused on in this experiment). Similarly, 
comparing the treated flies to those treated with L-DOPA treatment would demonstrate the applicability of the Mpe treatment used in this 
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